RE: Continued erosion20 Jan 2022 12:53
Just a reminder for those who seem to want something today - I too may be concerned but only by April ;
2022 Annual Report - ".....SDC-1801 is a selective dual tyrosine kinase 2 ("TYK2") / Janus kinase 1 ("JAK1") inhibitor, discovered by Sareum. We have been advancing SDC-1801 through preclinical development and preparing for clinical trials to investigate its potential for treating autoimmune diseases, such as psoriasis, lupus, inflammatory bowel diseases, rheumatoid arthritis as well as severe respiratory symptoms of Covid-19.
We are pleased to report that the final toxicology and safety studies required to file for an exploratory Clinical Trial Authorisation ("CTA") have been completed and we expect the finalised reports in the first quarter of 2022. The data from these studies will be crucial to the progression of this CTA, which we remain on track to submit during mid-2022. While data analysis is still in progress, we are confident that the studies have met their objectives of identifying any organs or tissues that might be susceptible to high-dose toxicity and determining the appropriate first-in-human dose. The results received to date fully support our plan to submit this CTA for SDC-1801.